Does Abiraterone Offer An Added Benefit Compared With The Present Standard Therapy For Metastatic Prostate Cancer?

Certain men with metastatic prostate cancer have advantages in comparison with watchful waiting Abiraterone acetate (abiraterone for short, trade name: Zytiga) has been approved in Germany since December 2012 for men with metastatic prostate cancer that is not responsive to hormone blockade, who only have mild symptoms or so far none at all, and in whom chemotherapy is not yet indicated... via Health News from Medical News Today Read More Here..